News and Media

2016/10/13 – Quantum Genomics announces 2016 first-half financial results and first nine months business update

13 October 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced its financial results for the first half of the year, approved by the Board of Directors at its meeting […]

2016/09/29 – Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

29 September 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced positive top-line results from its Phase IIa trial of lead candidate QGC001 in patients with hypertension (high blood […]

2016/09/22 – Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension

22 September 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will host a conference call on Thursday, September 29, 2016 at 12:00 p.m. Eastern […]

2016/09/12 – Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016

12 September 2016
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that it will release the results of the Phase IIa clinical trial for high blood pressure (QGC001 program) on […]